Drug Trial Radar · NCT06969430
A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
154
Planned (sponsor's estimate)
Start
May 30, 2025
Primary completion
Nov 2031
Study completion Nov 2031
Sponsor
- Lead sponsor
- Debiopharm International SAIndustry
- Sponsor type
- Industry
- First posted
- May 13, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of Phase 1 is to characterize the safety and tolerability to identify the recommended dose (RD) of Debio 1562M for further development. The primary objective of Phase 2 is to evaluate the antileukemic activity of Debio 1562M.
Conditions
- Acute Myeloid Leukemia
Interventions
Debio 1562MDrug
Administered as intravenous (IV) infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1 (Dose Escalation): Number of Participants Experiencing Dose-Limiting Toxicities (DLTs)Time frame: Up to Day 28
- Phase 1: Number of Participants With at Least One Treatment-Emergent Adverse Event (TEAE)Time frame: Up to Day 219
- Phase 1 (Dose Optimization): Recommended Dose (RD) of Debio 1562MTime frame: Up to Day 198
- Phase 2: Percentage of Participants With Complete Remission (CR) + CR with partial hematological recovery (CRh)Time frame: Up to Day 198
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
City of Hope Comprehensive Cancer Center
Duarte, California · Recruiting
Moffitt Cancer Center and Research Institute Hospital
Tampa, Florida · Recruiting
University of Chicago
Chicago, Illinois · Recruiting
START Midwest
Grand Rapids, Michigan · Recruiting
Roswell Park Comprehensive Cancer Center
Buffalo, New York · Recruiting
The Ohio Sate University
Columbus, Ohio · Recruiting
MD Anderson Cancer Center
Houston, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.